Targeting Dyslipidemia in the Metabolic Syndrome: An Update

Publisher： Bentham Science Publishers

E-ISSN： 1875-6212|8|4|450-463

ISSN： 1570-1611

Source： Current Vascular Pharmacology, Vol.8, Iss.4, 2010-01, pp. : 450-463

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Metabolic syndrome and cardiometabolic risk: An update

By Grassi Guido   Seravalle Gino   Quarti-Trevano Fosca   Dell'ro Raffaella   Bombelli Michele   Mancia Giuseppe  

Blood Pressure, Vol. 18, Iss. 1-2, 2009-04 ,pp. : 7-16

Informa Healthcare

Access to resources Recommend Favorite

Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes

By Grieve Stuart M   Ansquer Jean-Claude   Keech Anthony C  

Future Cardiology, Vol. 2, Iss. 6, 2006-11 ,pp. : 635-646

Future Medicine

Access to resources Recommend Favorite

Cardiovascular Disease Risk of Type 2 Diabetes Mellitus and Metabolic Syndrome: Focus on Aggressive Management of Dyslipidemia

By  

Current Diabetes Reviews, Vol. 1, Iss. 2, 2005-06 ,pp. : 127-135

Bentham Science Publishers

Access to resources Recommend Favorite

Brugada syndrome: an update

By Li Anthony   Behr Elijah R  

Future Cardiology, Vol. 9, Iss. 2, 2013-03 ,pp. : 253-271

Future Medicine

Access to resources Recommend Favorite

The Costs of Metabolic Syndrome in Italy

By Lucioni Carlo  

High Blood Pressure & Cardiovascular Prevention, Vol. 13, Iss. 2, 2006-01 ,pp. : 53-60

Adis International

Access to resources Recommend Favorite